亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Adjuvant Chemotherapy Versus Observation Following Resection for Patients With Nonmetastatic Poorly Differentiated Colorectal Neuroendocrine Carcinomas

医学 危险系数 比例危险模型 四分位间距 内科学 置信区间 肿瘤科 结直肠癌 队列 阶段(地层学) 切除缘 生存分析 化疗 癌症 外科 切除术 古生物学 生物
作者
Rui Mao,Kan Li,Jianqiang Cai,Sheng Luo,Megan C. Turner,Dan G. Blazer,Hong Zhao
出处
期刊:Annals of Surgery [Lippincott Williams & Wilkins]
卷期号:274 (2): e126-e133 被引量:28
标识
DOI:10.1097/sla.0000000000003562
摘要

Objective: The aim of this study was to determine whether adjuvant chemotherapy (AC) provides a survival benefit in patients with nonmetastatic poorly differentiated colorectal neuroendocrine carcinomas (CRNECs) following resection. Background: There is little evidence to support the association between use of AC and improved overall survival (OS) in patients with CRNECs. Methods: Patients with resected non-metastatic CRNECs were identified in the National Cancer Database (2004–2014). Inverse probability of treatment weighting (IPTW) method was used to reduce the selection bias. IPTW-adjusted Kaplan-Meier curves and Cox proportional hazards models were used to compare OS of patients in different treatment groups. Results: A total of 806 patients diagnosed between 2004 and 2014 met the study entry criteria. Of these, 394 patients (48.9%) received AC. IPTW-adjusted Kaplan-Meier curves showed that median OS was significantly longer for AC versus observation [57.4 (interquartile range, IQR, 14.8–153.8) vs 38.2 (IQR, 10.4–125.4) months; P = 0.007]. In IPTW-adjusted Cox proportional hazards regression analysis, AC was associated with a significant OS benefit [hazard ratio (HR) = 0.73, 95% confidence interval (CI) 0.64–0.84; P < 0.001]. The results were consistent across subgroups stratified by pathologic T stage, pathologic N stage, and surgical margin status. Subgroup analysis according to tumor location demonstrated improved OS in the adjuvant therapy cohort among patients with left-sided neuroendocrine carcinomas (HR, 0.55; 95% CI, 0.44–0.68), but not in those with right-sided disease (HR, 0.89; 95% CI, 0.74–1.07). Conclusions: Patients with nonmetastatic CRNECs may derive survival benefit from AC. These findings support current guidelines recommending AC in patients with poorly differentiated neuroendocrine carcinomas in the colon and rectum. Efforts in education and adherence to national guidelines for NECs are needed.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
7秒前
8秒前
阿巴阿巴发布了新的文献求助30
15秒前
子平完成签到 ,获得积分0
26秒前
灵剑山完成签到 ,获得积分10
31秒前
yf完成签到,获得积分10
31秒前
Criminology34应助科研通管家采纳,获得30
46秒前
Criminology34应助科研通管家采纳,获得10
46秒前
千早爱音应助科研通管家采纳,获得20
46秒前
思源应助研友_8RyzBZ采纳,获得10
59秒前
1分钟前
Zefinity完成签到,获得积分10
1分钟前
1分钟前
1分钟前
研友_8RyzBZ发布了新的文献求助10
1分钟前
研友_8RyzBZ完成签到,获得积分20
1分钟前
卧镁铀钳完成签到 ,获得积分10
1分钟前
阿巴阿巴完成签到,获得积分10
1分钟前
1分钟前
外向的涛完成签到,获得积分10
2分钟前
2分钟前
张六六完成签到 ,获得积分10
2分钟前
千早爱音应助科研通管家采纳,获得20
2分钟前
在水一方应助科研通管家采纳,获得10
2分钟前
2分钟前
漫步随心发布了新的文献求助10
2分钟前
3分钟前
waomi完成签到 ,获得积分10
3分钟前
www驳回了今后应助
3分钟前
3分钟前
Runjin_Hu发布了新的文献求助10
3分钟前
guan发布了新的文献求助10
3分钟前
漫步随心完成签到,获得积分20
3分钟前
852应助默默善愁采纳,获得10
3分钟前
Kinkrit完成签到 ,获得积分10
3分钟前
guan完成签到,获得积分10
3分钟前
朴实的映秋完成签到,获得积分10
3分钟前
dddd完成签到,获得积分10
4分钟前
WANWAN发布了新的文献求助10
4分钟前
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Kolmogorov, A. N. Qualitative study of mathematical models of populations. Problems of Cybernetics, 1972, 25, 100-106 800
FUNDAMENTAL STUDY OF ADAPTIVE CONTROL SYSTEMS 500
微纳米加工技术及其应用 500
Nanoelectronics and Information Technology: Advanced Electronic Materials and Novel Devices 500
Performance optimization of advanced vapor compression systems working with low-GWP refrigerants using numerical and experimental methods 500
Constitutional and Administrative Law 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 遗传学 催化作用 冶金 量子力学 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 5302418
求助须知:如何正确求助?哪些是违规求助? 4449576
关于积分的说明 13848484
捐赠科研通 4335789
什么是DOI,文献DOI怎么找? 2380540
邀请新用户注册赠送积分活动 1375535
关于科研通互助平台的介绍 1341770